605 related articles for article (PubMed ID: 26244412)
1. Primary Medical Treatment of Thyrotropin-Secreting Pituitary Adenomas by First-Generation Somatostatin Analogs: A Case Study of Seven Patients.
Rimareix F; Grunenwald S; Vezzosi D; Rivière LD; Bennet A; Caron P
Thyroid; 2015 Aug; 25(8):877-82. PubMed ID: 26244412
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.
Caron P; Arlot S; Bauters C; Chanson P; Kuhn JM; Pugeat M; Marechaud R; Teutsch C; Vidal E; Sassano P
J Clin Endocrinol Metab; 2001 Jun; 86(6):2849-53. PubMed ID: 11397898
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.
Yamada S; Fukuhara N; Horiguchi K; Yamaguchi-Okada M; Nishioka H; Takeshita A; Takeuchi Y; Ito J; Inoshita N
J Neurosurg; 2014 Dec; 121(6):1462-73. PubMed ID: 25237847
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide.
Kuhn JM; Arlot S; Lefebvre H; Caron P; Cortet-Rudelli C; Archambaud F; Chanson P; Tabarin A; Goth MI; Blumberg J; Catus F; Ispas S; Beck-Peccoz P
J Clin Endocrinol Metab; 2000 Apr; 85(4):1487-91. PubMed ID: 10770186
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions.
Bertherat J; Brue T; Enjalbert A; Gunz G; Rasolonjanahary R; Warnet A; Jaquet P; Epelbaum J
J Clin Endocrinol Metab; 1992 Aug; 75(2):540-6. PubMed ID: 1353505
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of the long-acting octreotide formulation in patients with thyroid-stimulating hormone-secreting pituitary adenomas after incomplete surgery and octreotide treatment failure.
Zhang CF; Liang D; Zhong LY
Chin Med J (Engl); 2012 Aug; 125(15):2758-63. PubMed ID: 22931988
[TBL] [Abstract][Full Text] [Related]
7. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients.
Socin HV; Chanson P; Delemer B; Tabarin A; Rohmer V; Mockel J; Stevenaert A; Beckers A
Eur J Endocrinol; 2003 Apr; 148(4):433-42. PubMed ID: 12656664
[TBL] [Abstract][Full Text] [Related]
8. Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment.
Teramoto A; Sanno N; Tahara S; Osamura YR
Acta Neuropathol; 2004 Aug; 108(2):147-53. PubMed ID: 15185102
[TBL] [Abstract][Full Text] [Related]
9. Long-term preoperative management of thyrotropin-secreting pituitary adenoma with octreotide.
Iglesias P; Díez JJ
J Endocrinol Invest; 1998 Dec; 21(11):775-8. PubMed ID: 9972679
[TBL] [Abstract][Full Text] [Related]
10. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
[TBL] [Abstract][Full Text] [Related]
11. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
[TBL] [Abstract][Full Text] [Related]
12. Asymptomatic thyrotropin-secreting pituitary macroadenoma in a 13-year-old girl: successful first-line treatment with somatostatin analogs.
Rabbiosi S; Peroni E; Tronconi GM; Chiumello G; Losa M; Weber G
Thyroid; 2012 Oct; 22(10):1076-9. PubMed ID: 22947349
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and treatment of pituitary adenomas.
Chanson P; Salenave S
Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
[TBL] [Abstract][Full Text] [Related]
14. Long term treatment with the somatostatin analog SMS 201-995 in a patient with a thyrotropin- and growth hormone-secreting pituitary adenoma.
Wémeau JL; Dewailly D; Leroy R; D'Herbomez M; Mazzuca M; Decoulx M; Jaquet P
J Clin Endocrinol Metab; 1988 Mar; 66(3):636-9. PubMed ID: 2895119
[TBL] [Abstract][Full Text] [Related]
15. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
Boni G; Ferdeghini M; Bellina CR; Matteucci F; Castro Lopez E; Parenti G; Canapicchi R; Bianchi R
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
[TBL] [Abstract][Full Text] [Related]
16. [Thyrotropin-secreting pituitary adenomas].
Caron P
Presse Med; 2009 Jan; 38(1):107-11. PubMed ID: 18980829
[TBL] [Abstract][Full Text] [Related]
17. TSH-secreting pituitary adenomas: follow-up of 11 cases and review of the literature.
Ness-Abramof R; Ishay A; Harel G; Sylvetzky N; Baron E; Greenman Y; Shimon I
Pituitary; 2007; 10(3):307-10. PubMed ID: 17347873
[TBL] [Abstract][Full Text] [Related]
18. Pituitary macroadenoma secreting thyrotropin and growth hormone: remission of bihormonal hypersecretion in response to lanreotide therapy.
Shimon I; Nass D; Gross DJ
Pituitary; 2001 Sep; 4(4):265-9. PubMed ID: 12501978
[TBL] [Abstract][Full Text] [Related]
19. Surgical Outcome and Treatment of Thyrotropin-Secreting Pituitary Tumors in a Tertiary Referral Center.
Herguido NG; Fuentes ED; Venegas-Moreno E; Maorad LB; Flores-Martinez A; Ruiz PR; Dueñas MC; Roldán F; Fajardo E; Ruiz-Valdepeñas EC; Kaen A; Martín Schrader I; Cano DA; Soto-Moreno A
World Neurosurg; 2019 Oct; 130():e634-e639. PubMed ID: 31276853
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics of patients with thyrotropin-secreting pituitary adenoma.
Wu YY; Chang HY; Lin JD; Chen KW; Huang YY; Jung SM
J Formos Med Assoc; 2003 Mar; 102(3):164-71. PubMed ID: 12783133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
